
Hepatitis C: State of Medicaid Access Report Card

Wyoming



Grade	Recommendations to Improve Patient Access
B	• Remove prior authorization for HCV treatment. • Remove limit of one course of treatment per lifetime. • Remove additional restrictions as described below.

State Overview

As of July 2026, 59,127 individuals were enrolled in Medicaid and CHIP in Wyoming.[1] Wyoming has not expanded coverage to low-income adults.[2] Wyoming Medicaid does not contract with managed care organizations (MCOs).[3] In a federal analysis of 2023-2024 Medicaid claims data, less than 22% of Wyoming adult Medicaid beneficiaries newly identified with HCV received timely HCV treatment.[4]

The Wyoming Medicaid Preferred Drug List designates Mavyret and sofosbuvir/velpatasvir as preferred HCV treatment regimens.[5]

Deductions		Policy
Prior Authorization	-8	Prior authorization is required for all HCV treatment regimens.[6]
Fibrosis Restrictions		Wyoming Medicaid does not impose fibrosis restrictions.[7]
Substance Use Restrictions		Wyoming Medicaid does not impose substance use restrictions.[8]
Prescriber Restrictions		Wyoming Medicaid does not impose prescriber restrictions.[9]
Retreatment Restrictions	-8	Wyoming Medicaid appears to impose retreatment restrictions. The Prior Authorization Form notes that Wyoming allows only one course of treatment per lifetime.[10]
Access in Managed Care		Wyoming does not contract with MCOs.[11]
Additional Restrictions	-4	Wyoming Medicaid imposes additional restrictions as follows[12]: • Documentation of HCV genotype. • Documentation of adherence counseling: Wyoming Medicaid requires the prescriber to document patient's ability to adhere to treatment via a psychosocial readiness survey, PREP-C. Additionally, Wyoming Medicaid requires a commitment form to be signed by the patient and provider. The form notes that: "Non-compliance with the prescribed Hepatitis C regimen may put the client in jeopardy for denial of coverage in the future."[13]

Total Deductions	Total Score [100-Deductions]	Grade
-20	80	B

Contact Your State Officials

Medicaid Office[14]: Jesse Springer, State Medicaid Agent, Wyoming Department of Health
122 West 25th Street, 4 West, Cheyenne, WY 82002; Phone: (307) 777-7531

Pharmacy & Therapeutics Committee[15]: Aimee Lewis, DUR Manager, Wyoming Drug Utilization Review
1000 E. University Avenue, Dept. 3375, Laramie, WY 82071; Phone: 307-766-6750; Email: alewis13@uwyo.edu.

Key Sources

Preferred Drug List: Wyoming Medicaid, Preferred Drug List (Jun. 8, 2026)
Prior Authorization Form: Wyoming Medicaid, Prior Authorization Request Form – Hepatitis C Treatment (Dec. 2023)

---

[1] Centers for Medicare & Medicaid Services, Medicaid & Chip in Wyoming, https://perma.cc/8GCX-QCPM.
[2] Centers for Medicare & Medicaid Services, Medicaid & Chip in Wyoming, https://perma.cc/8GCX-QCPM.
[3] Kaiser Family Foundation, Medicaid Enrollment in Managed Care by Plan Type (2024), https://perma.cc/A92N-LTJC.
[4] U.S. Department of Health and Human Services, Office of Inspector General. *Less Than 25 Percent of Medicaid Beneficiaries With Hepatitis C Received Treatment Within 6 Months*. Data Brief OEI-BL-24-00450 (Nov. 2, 2026), https://perma.cc/PDA7-HQUM.
[5] Preferred Drug List.
[6] Preferred Drug List.
[7] Prior Authorization Form.
[8] Prior Authorization Form.
[9] Prior Authorization Form.
[10] Prior Authorization Form.
[11] Kaiser Family Foundation, Annual Medicaid Budget Survey for State Fiscal Years 2023 and 2024 (Nov. 14, 2023), https://perma.cc/4K6Y-8DEM.
[12] Prior Authorization Form.
[13] Prior Authorization Form.
[14] National Association of Medicaid Directors, https://perma.cc/9TLM-HSKZ.
[15] Wyoming Drug Utilization Review, https://perma.cc/LUY2-WZVX.